Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
FosD · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| FosD | EXPERIMENTAL | Four sequential cohorts of Japanese subjects are planned with doses ranging from 50mg once daily to a maximum of 200mg twice daily. One cohort of White subjects is also planned to receive the same dose regimen as the third dose level in Japanese subjects |
| Placebo | PLACEBO_COMPARATOR | Placebo given (2 subjects in each cohort) |
| Name | Type | Description |
|---|---|---|
| FosD | DRUG | oral tablet |
| Placebo | DRUG | oral tablet |
Inclusion Criteria: * Healthy male and female (of non-childbearing potential) Japanese subjects and White subjects (origins in Europe, the Middle East, or North Africa) * Body mass index (BMI) between 17 and 27 kg/m2 and weigh at least 45 kg and no more than 100 kg Exclusion Criteria: * History o...
FosD is the short name for fostamatinib disodium, a small molecule drug developed by AstraZeneca PLC. It has been studied in a Phase 1 clinical trial in healthy adult volunteers to assess safety, tolerability, and blood and urine drug levels. FosD is an investigational agent and is not approved for any indication.
FosD is being developed by AstraZeneca PLC, which trades under the ticker AZN. The company sponsored the Phase 1 trial of fostamatinib disodium in healthy Japanese and White subjects. AstraZeneca is the sole developer named for this asset.
FosD is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are ongoing. The completed study enrolled 56 healthy volunteers and evaluated safety, tolerability, and drug levels. FosD remains an investigational drug and has not received regulatory approval.
FosD has been evaluated in one completed Phase 1 trial, NCT01167868, titled "A Study to Assess the Safety, Tolerability, and Blood and Urine Drug Levels of Fostamatinib Disodium (FosD) in Healthy Japanese and White Subjects." The trial enrolled 56 healthy volunteers in the United States and was randomized, double-blind, and placebo-controlled.
Yes, FosD is an abbreviation for fostamatinib disodium. The two names refer to the same small molecule drug developed by AstraZeneca PLC. The Phase 1 trial NCT01167868 used both terms interchangeably in its title and documentation.